We have been using prolonged infusions (3 hours) for all #belalactam antibacterials for almost 10 years now in hospitalized patients, including those with febrile neutropenia, based on Dr. Drusano's work from the late 2000s. We'll need to report on our outcomes!
-
-
- Još 1 odgovor
Novi razgovor -
-
-
A conclusion limited by the use of a composite surrogate endpoint as the main outcome and subgroup analysis with less than 20 patients each…not practice changing yet.
-
Agree, but ads to other papers published recently... https://ccforum.biomedcentral.com/articles/10.1186/s13054-018-2155-1 … http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30615-1/fulltext …
- Još 1 odgovor
Novi razgovor -
-
-
Indeed - stability data also key here - We have just published fluclox stability https://ejhp.bmj.com/content/ejhpharm/early/2018/09/18/ejhpharm-2018-001515.full.pdf … with mero out soon, pip tax and ceftaz being worked up.
@eopat@BSACandJAC -
That's great, thanks for sharing. Very attractive the idea of using fluclox infusion in OPAT. Always feel uncomfortable giving out unnecessary antibiotic spectrum with ceftriaxone for staphylococcal SSTI.
- Još 6 drugih odgovora
Novi razgovor -
-
-
Yes! I used to use it 10 years ago in a setting with higher R than the UK. Much more sense for isolates with highish MIC than short infusion
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
-
-
For monomicrobial infections e.g. SAB surely a no brainier but is there concern in potentially polymicrobial ones e.g. HAP (or even FNE)?
@APTlivuniHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.